SAT0225 Comparative effectiveness in pain and haq-di improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naÏve rheumatoid arthritis patients: a matching-adjusted indirect comparison (MAIC)
Authors: B. Fautrel, B. Zhu, P. C. Taylor, M. van de Laar, P. Emery, F. De Leonardis, C. Gaich, C. Nicolay, Z. Kadziola, I. De La Torre, R. Fleischmann
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> In Phase 3 trial, RA-BEGIN, baricitinib (BARI) monotherapy demonstrated superiority to MTX in pain reduction and HAQ-DI improvement in treatment of csDMARD-naïve active RA patients.<sup>1</sup> No prospective head-to-head (H2H) trial data are available comparing BARI monotherapy vs. bDMARD monotherapy in csDMARD-naïve RA patients. <h3>Objectives:</h3> To assess pain and HAQ-DI for BARI monotherapy from a randomized, MTX-controlled trial vs adalimumab (ADA), tocilizumab (TCZ), and tofacitinib (TOFA) monotherapy from similar randomized, MTX-controlled trials in csDMARD/bDMARD naïve RA patients using matching-adjusted indirect comparison (MAIC). <h3>Methods:</h3> Individual patient data from the RA-BEGIN BARI 4 mg arm were weighted to match baseline characteristics of the ADA arm from PREMIER,<sup>2</sup> TOFA 5 mg arm from ORAL-START,<sup>3</sup> and TCZ 8 mg/kg arm from combination of AMBITION and FUNCTION,<sup>4,5</sup> respectively; MTX arms were also matched between trials. Method of moments was used to determine weights for age, gender, baseline disease scores, and baseline values of the outcome variable. Mean change on pain VAS and HAQ-DI at Week 24 for BARI were adjusted for the above baseline characteristics with the weighted linear model, and then indirectly compared vs. respective published results for Week 24 TCZ and TOFA and for Week 26 ADA data. Statistical significance of the weighted treatment effect was assessed with the bootstrap method. Sensitivity analyses included MAIC with study level matching<sup>6</sup>, Bucher's method without matching adjustment<sup>7</sup>, and inclusion of disease duration as an additional matching variable. <h3>Results:</h3> Across trials, the mean baseline pain VAS ranged from 58.7 to 65.2 with a 6-month mean change in pain of -28.3 to -33.5 for the MTX arm, indicating comparability between trials. Similar HAQ-DI and changes in HAQ-DI for the MTX arm were observed. At Week 24, BARI showed numerically greater improvement over MTX in pain than that for TCZ, ADA, and TOFA; statistically significant pain improvement were observed for BARI vs ADA and TCZ with all 3 matching methods but only with the Bucher method for TOFA (figure 1). BARI-treated patients showed significantly greater improvement in HAQ-DI at Week 24 than TCZ and ADA but not TOFA (figure 1). Sensitivity analyses showed consistent results. <h3>Conclusions:</h3> This indirect comparison of different studies in cs/bDMARD-naïve RA patients, after adjusting for differences in baseline characteristics, suggest a greater pain reduction and improved physical function for BARI monotherapy vs. TCZ and ADA monotherapy. There is suggestion of greater pain reduction for BARI monotherapy vs. TOFA monotherapy, but no differences in improved physical function between the JAK inhibitors. A H2H clinical trial would be needed to confirm these results. <h3>References</h3> 1Fleischmann, et al. Arthritis Rheumatol2017. 2Breedveld, et al. Arthritis Rheumatol2006. 3Lee, et al. N Engl J Med2014. 4Jones, et al. Ann Rheum Dis2010. 5Burmester, et al. Ann Rheum Dis2016. 6Signorovitch, et al. Pharmacoeconomics2010. 7Bucher, et al. J Clin Epi1997. <h3>Disclosure of Interest:</h3> B. Fautrel Grant/research support from: AbbVie, MSD, Pfizer, Consultant for: AbbVie, Biogen, BMS, Celgene, Janssen, Lilly, Medac, MSD, NORDIC Pharma, Novartis, Pfizer, Roche, Sanofi-Aventis, SOBI, UCB, B. Zhu Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, P. Taylor Grant/research support from: Celgene, Eli Lilly and Company, Galapagos, UCB, Abide Therapeutics, Consultant for: AbbVie, Eli Lilly and Company, Galapagos, GlaxoSmithKline, Pfizer, UCB, Biogen, Sandoz, Novartis, and Janssen, M. van de Laar Grant/research support from: Abbvie; BMS; Grunenthal; Pfizer; Janssen; MSD, Lilly, Consultant for: Abbvie, Grunenthal; Pfizer, Janssen, MSD, Lilly, Speakers bureau: Pfizer; Janssen, Eli Lilly, P. Emery Consultant for: Pfizer, MSD, Abbvie, BMS, UCB, Roche, Novartis, Samsung, Sandoz, Eli Lilly and Company, F. De Leonardis Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, C. Gaich Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, C. Nicolay Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Z. Kadziola Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, I. De La Torre Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, R. Fleischmann Grant/research support from: AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Genetech, GlaxoSmithKline, Janssen, Eli Lilly and Company, Merck, Pfizer, Regeneron, Roche, Sanofi, Aventis, UCB, Consultant for: AbbVie, Akros, Amgen, Bristol-Myers Squibb, Celgene, Genentech, GSK, Janssen, Eli Lilly and Company, Pfizer, Sanofi-Aventis, UCB